400客服电话
购买数据产品
400-9696-311 转1
定制咨询业务
400-9696-311 转2
数据与AI定制业务
400-9696-311 转3
商务合作及其他问题
400-9696-311 转4
投诉及建议
400-9696-311 转5
ChiCTR2000040970
正在进行
/
/
/
2020-12-16
/
/
Caregivers of palliative care patients
An Acceptance and Commitment Therapy – Caregiver Support Program (ACT-CSP) for family caregivers of patients receiving palliative care: A feasibility study
An Acceptance and Commitment Therapy – Caregiver Support Program (ACT-CSP) for family caregivers of patients receiving palliative care: A feasibility study
1) To test the feasibility, acceptability and preliminary efficacy of an acceptance and commitment therapy for supporting caregiver programme (ACT-CSP) on reduction of caregiver burden, anxiety and depressive symptoms and enhancement of caregiving self-efficacy, resilience and quality of life by ACT when compared to usual care, for caregivers of palliative care patients; 2) To explore ACTs potential impact on patients symptom burden.
随机平行对照
其它
After collecting participant's informed consent, a research assistant will randomly assign the participant to either ACT-CSP or TAU arm using the pre-prepared envelopes. Caregivers will be randomized to either the two arms by block randomization with varying block sizes.
Both the caregivers and the intervention facilitator cannot be blinded due to the intervention nature. All the outcome assessors will be blinded.
Departmental General Research Fund
/
40
/
2021-02-01
2023-01-31
/
Caregivers will be eligible if they are (1) aged >=18 years; (2) self- or patient-identified as a family caregiver of an adult patient receiving palliative care at the study site; (3) have been taking care of the patient in the past 3 months; (4) able to communicate in Cantonese at the time of recruitment；
请登录查看Caregivers will be excluded if they are (1) mentally incompetent (Mini-Mental State Examination (MMSE) < 23); (2) participating in regular psychosocial interventions.；
请登录查看香港理工大學護理學院
/
德琪医药2026-07-20
动脉网-最新2026-07-20
药精通Bio2026-07-20
求实药社2026-07-20
求实药社2026-07-20
康方生物Akeso2026-07-20
干细胞与外泌体2026-07-20
加科思2026-07-20
良医汇肿瘤资讯2026-07-19
GLP1减重宝典2026-07-19
400-9696-311 转1
400-9696-311 转3
400-9696-311 转4
400-9696-311 转5
川公网安备51019002008863号
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
“坚决打赢禁毒人民战争”专栏 法律法规 | 美、墨、欧盟管制品种
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
